Pharma Gets 340B Appeals Court Victory But More Decisions Are Pending; Will Congress Step In?
Third Circuit is first of three federal appeals courts to issue a decision in multiple lawsuits over drug companies’ 340B contract pharmacy restrictions, which have led to conflicting lower court rulings on whether such restrictions are unlawful.
You may also be interested in...
340B Court Decision Threatens To Expand Patient Eligibility; Can Pharmacy Restrictions Counter Program Growth?
Court ruling in litigation brought against the US government by Genesis Healthcare may elicit competing reactions among stakeholders but is expected to stir up the 340B market.
PhRMA points to federal court rulings against HHS’s view that companies cannot limit discounts to contract pharmacies. However, there is a split among district courts and while one appellate court has sided with industry two have yet to issue opinions.
Research is published as the US Congress gears up to explore reforms of the 340B program. The findings align with pharma’s push to ‘share the savings’ but are not currently typical in the program, the Pharmaceutical Research and Manufacturers of America maintains.